Please provide your email address to receive an email when new articles are posted on . Patients with cardiac amyloidosis who were carefully selected for heart transplantation had similar outcomes ...

Background Amyloid transthyretin (ATTR) amyloidosis is a rare, life-threatening disease frequently manifesting with ...

BOYNTON BEACH, Fla. — In the last five years, Dennis Ennis has lost five of his 12 siblings to congestive heart failure, but he didn’t consider his own risk, even when he started having shortness of ...

Since 2019, three disease-specific therapies have been approved to treat patients with ATTR-CM. The first was Pfizer’s Vyndamax (tafamidis) in May 2019, which was approved for both wild type and ...

Screening for cardiac amyloidosis and excluding patients with cardiac amyloidosis from trials of new therapies for heart failure with preserved ejection fraction (HFpEF) may increase the chances of ...

A report from the World Heart Federation provides an overview of transthyretin amyloid cardiomyopathy (ATTR-CM), including tools for diagnosis and patient management, highlighting the importance of ...

Heart transplant is a viable treatment option for adults at an advanced stage of cardiac amyloidosis, as overall survival after transplantation has continued to improve over 3 decades, data from a ...

A type of heart failure caused by a build-up of amyloid can be accurately diagnosed and prognosticated with an imaging technique, eliminating the need for a biopsy, according to a multicenter study ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Tenosynovial tissue sampling at the time of carpal tunnel ...

The Chattanooga Heart Institute announces the opening of its new Martin Cardiac Amyloidosis Center of Excellence in honor of Dr. Henry Cheng, the first of its kind in the region. This specialized ...